History

1991
Pharmalink and Linc are foundedĀ 

1993
Acquisition of Stille AB

1999
The main project in Calliditas is acquired
Listing of Stille AB

2004
New Pharmalink is formed, projects are separated into their own company (current Calliditas Therapeutics) and sales of product portfolio begin

2005
Pharmalink sells product portfolio to Meda
Sedana Medical is founded

2007
Investment in MedCap

2008
Acquisition of shares in nWise AB

2012
Acquisition of shares in Swevet

2013
Investment in Animal Probiotics

2014
Acquisition of shares in Arcoma

2015
Investment in Athera Biotechnologies

2016
Sale of the holding in Meda
Sale of the holding in Bringwell
Sale of the holding in Boule
Investment in Cinclus

2017
Acquisition of shares in Medivir
Listing of Sedana

2018
Listing of Calliditas in Stockholm
Acquisition of shares in Elos
Investment in Index Pharmacuticals
Investment in Sciety
Investment In Gesynta

2019
Founding of Part Production
Sale of the holding in Midsona

2020
Investment in Epicyt
Investment in Synatro
Investment in Fluoguide
Listing of Callidita’s shares in the USA
Investment in Sixera
Investment in OncoZenge
Investment in AdderaCare
Karl Tobieson is appointed CEO and Thomas Bergh CFO of Linc